Survival Outcome of Partial Cystectomy versus Transurethral Bladder Tumor Resection in T1 High-Grade Bladder Cancer Patients: A Propensity Score Matching Study
Table 2
Clinicopathological features between RC and PC before and after propensity score matching.
Variables
No PSM
PSM
RC (n = 438)
PC (n = 190)
value
RC (n = 160)
PC (n = 190)
value
Age (year)
Mean ± SD
67.9 ± 9.625
71.5 ± 9.830
<0.001∗
69.9 ± 9.408
71.5 ± 9.830
0.121
Median (25th–75th percentile)
67.5 (62–72)
72 (66–77.5)
<0.001∗
72 (62–77.5)
72 (66–77.5)
0.063
Sex
0.968
0.817
Female
64 (14.6%)
28 (14.7%)
25 (15.6%)
28 (14.7%)
Male
374 (85.4%)
162 (85.3%)
135 (84.4%)
162 (85.3%)
Race
0.496
0.318
White
387 (88.4%)
171 (90.0%)
144 (90.0%)
171 (90.0%)
Black
25 (5.7%)
12 (6.3%)
6 (3.8%)
12 (6.3%)
Other style
26 (5.9%)
7 (3.7%)
10 (6.3%)
7 (3.7%)
Marital status
0.826
0.393
Married
301 (68.7%)
132 (69.5%)
117 (73.1%)
132 (69.5%)
SDW
74 (16.9%)
34 (17.9%)
30 (18.8%)
34 (17.9%)
Single
63 (14.4%)
24 (12.6%)
13 (8.1%)
24 (12.6%)
Grade
0.703
0.215
Grade I or Grade II
9 (2.1%)
6 (3.2%)
1 (0.6%)
6 (3.2%)
Grade III
95 (21.7%)
40 (21.1%)
38 (23.8%)
40 (21.1%)
Grade IV
334 (76.3%)
144 (75.8%)
121 (75.6%)
144 (75.8%)
Histology
0.13
0.602
TCC
185 (42.2%)
68 (35.8%)
53 (33.1%)
68 (35.8%)
PTCC
253 (57.8%)
122 (64.2%)
107 (66.9%)
122 (64.2%)
Radiotherapy
0.653
0.403
No/unknown
433 (98.9%)
187 (98.4%)
159 (99.4%)
187 (98.4%)
Yes
5 (1.1%)
3 (1.6%)
1 (0.6%)
3 (1.6%)
Chemotherapy
0.842
0.868
No/unknown
345 (78.8%)
151 (79.5%)
126 (78.8)
151 (79.5%)
Yes
93 (21.2%)
39 (20.5%)
34 (21.3%)
39 (20.5%)
Tumor size
<0.001∗
0.042∗
≤3 cm
323(73.7%)
78 (41.1%)
87 (54.4%)
78 (41.1%)
3–6 cm
86(19.6%)
74 (38.9%)
46 (28.7%)
74 (38.9%)
>6 cm
29 (6.6%)
38 (20.0%)
27 (16.9%)
38 (20.0%)
Tumor site
<0.001∗
0.041∗
Trigone
14 (3.2%)
1 (0.5%)
8 (5.0%)
1 (0.5%)
Dome
17 (3.9%)
29 (15%)
15 (9.4%)
29 (15.3%)
Lateral
49 (11.2%)
30 (15.8%)
34 (21.3%)
30 (15.8%)
Anterior
11 (2.5%)
10 (5.3%)
7 (4.4%)
10 (5.3%)
Posterior
29 (6.6%)
22 (11.6%)
12 (7.5%)
22 (11.6%)
Bladder neck
11 (2.5%)
2 (1.1%)
4 (2.5%)
2 (1.1%)
Ureteric orifice
6 (1.4%)
4 (2.1%)
1 (0.6%)
4 (2.1%)
Other sites
301 (68.7%)
92 (48.4%)
79 (49.4%)
92 (48.4%)
Number of tumor
<0.001∗
0.457
Single
183 (41.8%)
112 (58.9%)
88 (55.0%)
112 (58.9%)
Multiple
255 (58.2%)
78 (41.1%)
72 (45.0%)
78 (41.1%)
Survival time (month)
Mean
60.021
55.121
0.40
59.106
55.121
0.196
Median (25th–75th percentile)
62 (39–86)
55.5 (37–77)
0.038∗
60.5 (39–82.75)
55.5 (37–77)
0.157
PC: partial cystectomy; RC: radical cystectomy; other race: American/Indian/Alaska/native/Asian/Pacific Islande; SDW: separated, divorced or widowed; other sites: overlapping lesion of bladder, bladder, NOS; TCC: transitional cell carcinoma, PTCC: papillary transitional cell carcinoma. PSM, propensity score matching. ∗Statistically significant.
